Skip to main content
SpringerLink
Log in

Graft Manipulation: T Cell Depletion and Tumor Cell Purging

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial. Lancet. 2005;366: 733–41.

    PubMed  CAS  Google Scholar 

  2. Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopoulos E et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005;106: 3308–13.

    PubMed  CAS  Google Scholar 

  3. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglu-tinin and sheep red blood cells. Lancet. 1981;2: 327.

    PubMed  CAS  Google Scholar 

  4. De Witte T, Hoogenhout J, de Pauw B, Holdrinet R, Janssen J, Wessels J et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. Blood. 1986;67: 1302–1308.

    PubMed  Google Scholar 

  5. Noga SJ, Donnenberg AD, Schwartz CL, Strauss LC, Civin CI, Santos GW. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation. 1986;41: 220–228.

    PubMed  CAS  Google Scholar 

  6. Wagner JE, Donnenberg AD, Noga SJ, Cremo CA, Gao IK, Yin HJ et al. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988;72: 1168–1176.

    PubMed  CAS  Google Scholar 

  7. Prentice HG, Blacklock HA, Janossy G et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft versus host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet. 1982;1: 700.

    PubMed  CAS  Google Scholar 

  8. Filipovich AH, McGlave PB, Ramsay NKC et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft versus host disease in allogeneic histocompatible bone marrow transplantation. Lancet. 1982;1: 1266.

    PubMed  CAS  Google Scholar 

  9. Martin PJ, Hansen JA, Thomas ED. Preincubation of donor bone marrow cells with a combination of murine monclonal anti-T-cell antibodies without complement does not prevent graft-versus-host disease after allogeneic marrow trasnplantation. Journal of Clinical Immunology. 1984;4: 18–22.

    PubMed  CAS  Google Scholar 

  10. Waldmann HG, Hale G, Cividalli G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet. 1984;2: 483–486.

    PubMed  CAS  Google Scholar 

  11. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26: 69–76.

    PubMed  CAS  Google Scholar 

  12. Henslee-Downey PJ, Parrish RS, MacDonald JS, Romond EH, Marciniak E, Coffey C et al. Combined in vitro and in vivo T lymphocyte depletion for thecontrol of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61: 738–45.

    PubMed  CAS  Google Scholar 

  13. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100: 3121–7.

    PubMed  CAS  Google Scholar 

  14. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334: 281–5.

    PubMed  CAS  Google Scholar 

  15. Martin PJ, Hansen JA. Quantitative assays for detection of residual T cells in T-depleted human marrow. Blood. 1985;65: 1134–1140.

    PubMed  CAS  Google Scholar 

  16. Kernan NA, Collins NH, Juliano L, Cartagena BS, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood. 1986;68: 770–773.

    PubMed  CAS  Google Scholar 

  17. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood. 2001;97: 383–7.

    PubMed  CAS  Google Scholar 

  18. Bornhauser M, Platzbecker U, Theuser C, Holig K, Ehninger G. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol. 2002;118: 1095–103.

    PubMed  Google Scholar 

  19. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood. 2002;100: 724–7.

    PubMed  CAS  Google Scholar 

  20. Bahceci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br Journal of haematology. 2000;108: 408–14.

    CAS  Google Scholar 

  21. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98: 3221–7.

    PubMed  CAS  Google Scholar 

  22. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood. 2001;98: 2352–7.

    PubMed  CAS  Google Scholar 

  23. Ringden O, Barrett AJ, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003;121: 874–85.

    PubMed  Google Scholar 

  24. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95: 3996–4003.

    PubMed  CAS  Google Scholar 

  25. Rodt H, Kolb HJ, Netzel B, Haas RJ, Wilms K, Gotze CB et al. Effect of Anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplantation Proceedings. 1981;13: 257–261.

    PubMed  CAS  Google Scholar 

  26. Prentice HG, Janossy G, Price-Jones L et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leuke-mic marrow transplant recipients. Lancet. 1984;1: 472–475.

    PubMed  CAS  Google Scholar 

  27. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66: 664-672.

    PubMed  CAS  Google Scholar 

  28. Trigg ME, Billing R, Sondel PM, Exten R, Hong R, Bozdech MJ et al. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched alloge-neic bone marrow transplants. Cancer Treatment Reports. 1985;69: 377–386.

    PubMed  CAS  Google Scholar 

  29. Herve P, Flesch M, Cahn JY et al. Removal of marrow T cells with OKT3–OKT11 monoclonal antibodies and complement to prevent graft-versus-host disease. Transplantation. 1985;39: 138–143.

    PubMed  CAS  Google Scholar 

  30. Hale G, Cobbold S, Waldmann H. T-cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation. 1988;45: 753–759.

    PubMed  CAS  Google Scholar 

  31. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;78: 2139–49.

    PubMed  CAS  Google Scholar 

  32. Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. Journal of Clinical Oncology. 1992;10: 1191–2000.

    PubMed  CAS  Google Scholar 

  33. Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G et al. Selective depletion of CD8– T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76: 418–423.

    PubMed  CAS  Google Scholar 

  34. Jansen J, Hanks S, Akard L, Martin M, Thompson J, Chang Q et al. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15: 271–8.

    PubMed  CAS  Google Scholar 

  35. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation. 1994;57: 82–87.

    PubMed  CAS  Google Scholar 

  36. Young JW, Papadopoulos EB, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi MH et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood. 1992;79: 3380–7.

    PubMed  CAS  Google Scholar 

  37. Wagner JE, Santos GW, Noga SJ, Rowley SD, Davis J, Vogelsang GB et al. Bone marrow graft engineering by counterflow elutriation: Results of a phase I–II clinical trial. Blood. 1990;75: 1370–1377.

    PubMed  CAS  Google Scholar 

  38. O'Donnell PV, Myers B, Edwards J, Loper K, Rhubart P, Noga SJ. CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts. Cytotherapy. 2001;3: 483–8.

    PubMed  Google Scholar 

  39. Link H, Arseniev L, Bahre O, Kadar JG, Diedrich H, Poliwoda H. Transplantation of allogeneic CD34+ blood cells. Blood. 1996;87: 4903–9.

    PubMed  CAS  Google Scholar 

  40. Bensinger WI, Buckner CD, Shannon-Dorcy K, Rowley S, Appelbaum FR, Benyunes M et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood. 1996;88: 4132–8.

    PubMed  CAS  Google Scholar 

  41. Urbano-Ispizua A, Solano C, Brunet S, de la Rubia J, Odriozola J, Zuazu J et al. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Bone Marrow Transplant. 1998;22: 519–25.

    PubMed  CAS  Google Scholar 

  42. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328: 593–602.

    PubMed  CAS  Google Scholar 

  43. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83: 1980–1987.

    PubMed  CAS  Google Scholar 

  44. Marks DI, Bird JM, Vettenranta K, Hunt L, Green A, Cornish JM et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2000;6: 646–53.

    PubMed  CAS  Google Scholar 

  45. Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC et al. CD6+ Donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J. Clin. Oncol. 2001;19: 1152–1159.

    PubMed  CAS  Google Scholar 

  46. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98: 2942–7.

    PubMed  CAS  Google Scholar 

  47. Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D et al. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997;3: 11–7.

    PubMed  CAS  Google Scholar 

  48. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89: 3864–72.

    PubMed  CAS  Google Scholar 

  49. Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv F et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 2004;33: 389-–96.

    PubMed  CAS  Google Scholar 

  50. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991;7: 443–52.

    PubMed  CAS  Google Scholar 

  51. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339: 1186–93.

    PubMed  CAS  Google Scholar 

  52. Marks DI, Khattry N, Cummins M, Goulden N, Green A, Harvey J et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol. 2006;134: 196–201.

    PubMed  Google Scholar 

  53. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007.

    Google Scholar 

  54. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood. 1999;94: 333–9.

    PubMed  CAS  Google Scholar 

  55. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102: 814–9.

    PubMed  CAS  Google Scholar 

  56. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants.Killer immunoglobulin-like receptor. Blood. 2002;100: 3825–7.

    PubMed  CAS  Google Scholar 

  57. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12: 876–84.

    PubMed  CAS  Google Scholar 

  58. Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13: 965–974.

    PubMed  CAS  Google Scholar 

  59. Sivula J, Volin L, Porkka K, Vettenranta K, Itala M, Partanen J et al. Killer-cell immu-noglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation. Transpl Immunol. 2007;18: 62–6.

    PubMed  CAS  Google Scholar 

  60. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphob-lastic leukemia. Leukemia. 2007.

    Google Scholar 

  61. Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991;52: 1014–9.

    PubMed  CAS  Google Scholar 

  62. Moscardo F, A. U-I, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2003;31: 545–50.

    PubMed  Google Scholar 

  63. Breuer R, Or R, Lijovetzky G, Naparstek E, Engelhard D, Lafair J et al. Interstitial pneumonitis in T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1988;3: 625–30.

    PubMed  CAS  Google Scholar 

  64. Ho VT, Weller E, Lee SJ, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7: 223–229.

    PubMed  CAS  Google Scholar 

  65. Storb R, Prentice RL, Thomas ED et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anemia. British Journal of Haematology. 1983;55: 573–585.

    PubMed  CAS  Google Scholar 

  66. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73: 606–613.

    PubMed  CAS  Google Scholar 

  67. Deeg HJ, Self S, Storb R, Doney K, Appelbaum FR, Witherspoon RP et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood. 1986;68: 1363–1368.

    PubMed  CAS  Google Scholar 

  68. Patterson J, Prentice HG, Brenner MK et al. Graft rejection following HLA matched T-lymhpocyte depleted bone marrow transplantation. British Journal of Haematology. 1986;63: 221–230.

    PubMed  CAS  Google Scholar 

  69. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med. 1986;105: 20–6.

    PubMed  CAS  Google Scholar 

  70. Filipovich AH, Vallera DA, Youle RJ et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. Transplantation. 1987;44: 62.

    PubMed  CAS  Google Scholar 

  71. O'Reilly R, Collins NH, Kernan N et al. Transplantation of marrow-depleted T cells by soybean lectin agglutination and E-rosette depletion: major histocompat-ibility complex-related graft resistance in leukemic transplant patients. Transplant Proceedings. 1985;17: 455.

    Google Scholar 

  72. Lowenberg B, Wagemaker E, van Bekkum DW et al. Graft-versus-host disease following transplantation of “one log” versus “two log” T-lymphocyte depleted bone marrow from HLA-identical donors. Bone Marrow Transplantation. 1986;1: 133–140.

    PubMed  CAS  Google Scholar 

  73. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Pico JL, Leblond V et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemia. Lancet. 1987;2: 175–178.

    PubMed  CAS  Google Scholar 

  74. Maraninchi D, Mawas C, Guyotat D et al. Selective depletion of marrow-T cyto-toxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allo-geneic bone marrow transplantation. Transplant Int. 1988;1: 91–94.

    CAS  Google Scholar 

  75. Martin PJ, Hansen JA, Torok-Storb B et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 1988;3: 437–444.

    PubMed  CAS  Google Scholar 

  76. Laurent G, Maraninchi D, Gluckman E et al. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease. Bone Marrow Transplantation. 1989;4: 367–371.

    PubMed  CAS  Google Scholar 

  77. Hale G, Waldmann H, users fC. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplantation. 1994;13: 597–611.

    PubMed  CAS  Google Scholar 

  78. Kernan NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B et al. Graft failure after T-cell-depleted leukocyte antigen identical marrow transplants for leukemia: I. analysis of risk factors and results of secondary transplants. Blood. 1989;74: 2227–2236.

    PubMed  CAS  Google Scholar 

  79. Delain M, Cahn JY, Racadot E et al. Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients. Leukemia Lymphoma. 1993;11: 359–368.

    PubMed  CAS  Google Scholar 

  80. Herve P, Cahn JG, Flesch M et al. Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. Blood. 1987;69: 388–393.

    PubMed  CAS  Google Scholar 

  81. Martin PJ, Hansen JA, Torok-Storb B et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplantation. 1988;3: 445–456.

    PubMed  CAS  Google Scholar 

  82. Marmont A, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78: 2120–2130.

    PubMed  CAS  Google Scholar 

  83. Sondel PM, Hank JA, Trigg ME et al. Transplantation of HLA-haploidentical T cell-depleted marrow for leukemia: Autologous marrow recovery with specific immune sensitization to donor antigens. Experimental Hematology. 1986;14: 278–286.

    PubMed  CAS  Google Scholar 

  84. Bunjes D, Heit W, Arnold R et al. Evidence for the involvement of host derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation. 1987;43: 501.

    PubMed  CAS  Google Scholar 

  85. Bunjes D, Theobald M, Wiesneth M et al. Graft rejection by a population of primed CDw52-host T cells after in vivo/ex vivo T-depleted bone marrow transplantation. Bone Marrow Transplantation. 1993;12: 209–215.

    PubMed  CAS  Google Scholar 

  86. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T cell depleted HLA-nonidentical marrow transplants for leukemia. Transplantation. 1987;43: 842.

    PubMed  CAS  Google Scholar 

  87. Bierer BE, Emerson SG, Antin J, Maziarz R, Rappeport JM, Smith BR et al. Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation. Transplantation. 1990;49: 714–20.

    Google Scholar 

  88. Bordignon C, Keever CA, Small TN, Flomenberg N, Dupont B, O'Reilly RJ et al. Graft failure after T-cell-depleted leukocyte antigen identical marrow transplants for leukemia: II. in vitro analysis of host effector mechanisms. Blood. 1989;74: 2237–2243.

    PubMed  CAS  Google Scholar 

  89. Bosserman L, Murray C, Takvorian T et al. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplantion. 1989;4: 239–245.

    CAS  Google Scholar 

  90. Voogt PJ, Fibbe WE, Marjit WA et al. Rejection of bone marrow graft by recipient derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990;335: 135–144.

    Google Scholar 

  91. Fleischauer K, Kernan NA, O'Reilly RJ, Dupont B, Tang SY. Bone marrow-allo-graft rejection by T lymphocytes recognizing a single amino acid difference on HLA-B44. New England Journal of Medicine. 1990;323: 1818–1822.

    Google Scholar 

  92. Donohue J, Homge M, Kernan NA. Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor. Blood. 1993;82: 1023–9.

    PubMed  CAS  Google Scholar 

  93. Martin PJ, Rowley SD, Anasetti C, Chauncey TR, Gooley T, Petersdorf EW et al. A phase I–II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood. 1999;94: 2192–9.

    PubMed  CAS  Google Scholar 

  94. Reddehase MJ, Dreher-Stumpp L, Angele P, Balthesen M, Susa M. Hematopoietic stem cell deficiency resulting from cytomegalovirus infection of bone marrow stroma. Ann Hematol. 1992;64 Suppl: A125–7.

    PubMed  Google Scholar 

  95. Mutter W, Reddehase MJ, Busch FW, Buhring HJ, Koszinowski UH. Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalo-virus disease in the immunocompromised host. J Exp Med. 1988;167: 1645–58.

    PubMed  CAS  Google Scholar 

  96. Steffens HP, Podlech J, Kurz S, Angele P, Dreis D, Reddehase MJ. Cytomegalovirus inhibits the engraftment of donor bone marrow cells by downregulation of hemo-poietin gene expression in recipient stroma. J Virol. 1998;72: 5006–15.

    PubMed  CAS  Google Scholar 

  97. Johnston RE, Geretti AM, Prentice HG, Clark AD, Wheeler AC, Potter M et al. HHV-6-related secondary graft failure following allogeneic bone marrow transplantation. Br J Haematol. 1999;105: 1041–3.

    PubMed  CAS  Google Scholar 

  98. Rosenfeld CS, Rybka WB, Weinbaum D, Carrigan DR, Knox KK, Andrews DF et al. Late graft failure due to dual bone marrow infection with variants A and B of human herpesvirus-6. Exp Hematol. 1995;23: 626–9.

    PubMed  CAS  Google Scholar 

  99. Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant. 1995;15: 387–93.

    PubMed  CAS  Google Scholar 

  100. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant. 1996;18: 34.7–2013;53.

    PubMed  CAS  Google Scholar 

  101. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95: 2240–5.

    PubMed  CAS  Google Scholar 

  102. Guyotat D, Dutou L, Erhsam A et al. Graft rejection after T cell-depleted marrow transplantation: role of fractionated irradiation. British Journal of Haematology. 1987;65: 499–507.

    PubMed  CAS  Google Scholar 

  103. Burnett AK, Hann IM, Robertson AG et al. Prevention of graft-versus-host disease by ex vivo T cell depletion: Reduction in raft failure with augmented total body irradiation. Leukemia. 1988;2: 300–303.

    PubMed  CAS  Google Scholar 

  104. Bozdech MJ, Sondel PM, Trigg ME, Longo W, Kohler PC, Flynn B et al. Transplantation of HLA-haploindentical T-cell-depleted marrow for leukemia: Addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Experimental Hematology. 1985;13: 1201–1210.

    PubMed  CAS  Google Scholar 

  105. Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol. 2001;115: 95–104.

    PubMed  CAS  Google Scholar 

  106. Keever CA, Small TN, Flomenberg N, Heller G, Pekle K, Black P et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood. 1989;73: 1340–50.

    PubMed  CAS  Google Scholar 

  107. Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappeport JM, Keohan ML et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. Journal of Experimental Medicine. 1985;161: 1483–1502.

    PubMed  CAS  Google Scholar 

  108. Parreira A, Smith J, Hows JM, Smithers SA, Apperley J, Rombos Y et al. Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. Clin Exp Immunol. 1987;67: 142–50.

    PubMed  CAS  Google Scholar 

  109. Welte K, Keever CA, Levick J, Bonilla MA, Merluzzi VJ, Mertelsmann R et al. Interleukin-2 production and response to interleukin-2 by peripheral blood mono-nuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow. Blood. 1987;70: 1595–603.

    PubMed  CAS  Google Scholar 

  110. Soiffer RJ, Bosserman L, Murray C, Cochran K, Daley J, Ritz J. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990;75: 2076–84.

    PubMed  CAS  Google Scholar 

  111. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood. 1996;87: 3984–92.

    PubMed  CAS  Google Scholar 

  112. Roux E, Dumont-Girard F, Starobinski M, Siegrist CA, Helg C, Chapuis B et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood. 2000;96: 2299–303.

    PubMed  CAS  Google Scholar 

  113. Wu CJ, Chillemi A, Alyea EP, Orsini E, Neuberg D, Soiffer RJ et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95: 352–9.

    PubMed  CAS  Google Scholar 

  114. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72: 520–9.

    PubMed  CAS  Google Scholar 

  115. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71: 1234.

    PubMed  CAS  Google Scholar 

  116. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322: 485–94.

    PubMed  CAS  Google Scholar 

  117. Gerritsen EJ, Stam ED, Hermans J, van den Berg H, Haraldsson A, van Tol MJ et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant. 1996;18: 377–82.

    PubMed  CAS  Google Scholar 

  118. Martin P, Schulman H, Schubach W et al. Fatal Epstein-Barr virus associated proliferation of donor B-cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Annals of Internal Medicine. 1984;101: 310.

    PubMed  CAS  Google Scholar 

  119. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108: 2874–80.

    PubMed  CAS  Google Scholar 

  120. Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase, Importance of a graft-versus-leukaemia effect. British Journal of Haematology. 1988;69: 239–245.

    PubMed  CAS  Google Scholar 

  121. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine. 1988;108: 806–814.

    PubMed  CAS  Google Scholar 

  122. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75: 555–562.

    PubMed  CAS  Google Scholar 

  123. Martin P, Clift RA, Fisher LD, Buckner CD, Hansen JA, Appelbaum FR et al. HLA-identical marrow transplantation during accelerated-phase chronic myel-ogenous leukemia: analysis of survival and remission duration. Blood. 1988;72: 1978–1984.

    PubMed  CAS  Google Scholar 

  124. Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. British Journal of Haematology. 1992;81: 383–390.

    PubMed  CAS  Google Scholar 

  125. Wagner JE, Zahurak M, Piantadosi S, Geller RB, Vogelsang GB, Wingard JR et al. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. Journal of Clinical Oncology. 1992;10: 779–789.

    PubMed  CAS  Google Scholar 

  126. Gratwohl A, Hermans J, Niderwieser D, Frassoni F, Arcese W, Gahrton G et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplantation. 1993;12: 509–516.

    PubMed  CAS  Google Scholar 

  127. Weiden PL, Flournoy N, Thomas ED, Prentice R, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in recipients of allogeneic-marrow grafts. New England Journal of Medicine. 1979;300: 1068–1073.

    PubMed  CAS  Google Scholar 

  128. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73: 1720–1728.

    PubMed  CAS  Google Scholar 

  129. Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W et al. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myel-ogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood. 1996;88: 714–20.

    PubMed  CAS  Google Scholar 

  130. Kolb H, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76: 2462–2465.

    PubMed  CAS  Google Scholar 

  131. Collins RH, Jr., Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [see comments]. J Clin Oncol. 1997;15: 433–44.

    PubMed  Google Scholar 

  132. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81: 543–50.

    PubMed  CAS  Google Scholar 

  133. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83: 1980–7.

    PubMed  CAS  Google Scholar 

  134. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood. 1995;86: 3987–96.

    PubMed  CAS  Google Scholar 

  135. Devergie A, Apperley JF, Labopin M, Madrigal A, Jacobsen N, Carreras E et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20: 11–9.

    PubMed  CAS  Google Scholar 

  136. Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997;89: 3039–47.

    PubMed  CAS  Google Scholar 

  137. Bunjes D, Hertenstein B, Wiesneth M, Stefanic M, Novotny J, Duncker C et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant. 1995;15: 563–8.

    PubMed  CAS  Google Scholar 

  138. Remberger M, Ringden O, Aschan J, Ljungman P, Lonnqvist B, Markling L. Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplant Proc. 1994;26: 1829–30.

    PubMed  CAS  Google Scholar 

  139. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-ver-sus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102: 470–6.

    PubMed  CAS  Google Scholar 

  140. Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloab-lative allogeneic transplantation. Biol Blood Marrow Transplant. 2003;9: 453–9.

    PubMed  Google Scholar 

  141. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol. 2003;31: 865–72.

    PubMed  CAS  Google Scholar 

  142. Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D et al. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. Cytotherapy. 2003;5: 534–41.

    PubMed  CAS  Google Scholar 

  143. Glass B, Nickelsen M, Dreger P, Claviez A, Hasenkamp J, Wulf G et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lym-phoma effect. Bone Marrow Transplant. 2004;34: 391–7.

    PubMed  CAS  Google Scholar 

  144. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99: 4357–63.

    PubMed  CAS  Google Scholar 

  145. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia. 2003;17: 2168–77.

    PubMed  CAS  Google Scholar 

  146. Baron F, Schaaf-Lafontaine N, Humblet-Baron S, Meuris N, Castermans E, Baudoux E et al. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation. 2003;76: 1705–13.

    PubMed  CAS  Google Scholar 

  147. Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant. 2004;10: 186–94.

    PubMed  Google Scholar 

  148. Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG et al. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality. Ann Hematol. 2005;84: 331–8.

    PubMed  Google Scholar 

  149. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005;36: 797–802.

    PubMed  CAS  Google Scholar 

  150. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99: 1071–8.

    PubMed  CAS  Google Scholar 

  151. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103: 1548–56.

    PubMed  CAS  Google Scholar 

  152. Meyer RG, Britten CM, Wehler D, Bender K, Hess G, Konur A et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood. 2007;109: 374–82.

    PubMed  CAS  Google Scholar 

  153. Korngold R, Sprent J. T cell subsets and graft versus host disease. Transplantation. 1987;44: 335.

    PubMed  CAS  Google Scholar 

  154. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D et al. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant. 2005;35: 247–52.

    PubMed  CAS  Google Scholar 

  155. Ho VT, Kim HT, Li S, Hochberg EP, Cutler C, Lee SJ et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004;34: 987–94.

    PubMed  CAS  Google Scholar 

  156. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97: 2923–31.

    PubMed  CAS  Google Scholar 

  157. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant inter-leukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992;79: 517–526.

    PubMed  CAS  Google Scholar 

  158. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994;84: 964–971.

    PubMed  CAS  Google Scholar 

  159. Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF et al. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant. 2006;12: 1318–25.

    PubMed  Google Scholar 

  160. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110: 185–92.

    PubMed  CAS  Google Scholar 

  161. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174: 2591–601.

    PubMed  CAS  Google Scholar 

  162. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202: 907–12.

    PubMed  CAS  Google Scholar 

  163. Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 2001;61: 162–71.

    PubMed  CAS  Google Scholar 

  164. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99: 3083–8.

    PubMed  CAS  Google Scholar 

  165. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23: 1071–1079.

    PubMed  CAS  Google Scholar 

  166. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant. 2000;26 Suppl 2: S39–42.

    Google Scholar 

  167. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005;106: 1123–9.

    PubMed  CAS  Google Scholar 

  168. Vaclavkova P, Cao Y, Wu LK, Michalek J, Vitetta ES. A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro. Bone Marrow Transplant. 2006;37: 559–67.

    PubMed  CAS  Google Scholar 

  169. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts [see comments]. N Engl J Med. 1999;340: 1704–14.

    PubMed  CAS  Google Scholar 

  170. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97: 63–72.

    PubMed  CAS  Google Scholar 

  171. Aubin F, Cahn J Y, Ferrand C, Angonin R, Humbert P, Tiberghien P. Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase. Lancet. 2000;355: 626–7.

    PubMed  CAS  Google Scholar 

  172. Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highlypurified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997;89: 1334–40.

    PubMed  CAS  Google Scholar 

  173. Link CJ, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy JP et al. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. Hum Gene Ther. 1998;9: 115–34.

    PubMed  CAS  Google Scholar 

  174. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Anti-tumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem cell transplantation. Blood. 2007.

    Google Scholar 

  175. Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007.

    Google Scholar 

  176. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9: 243–56.

    PubMed  Google Scholar 

  177. Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12: 995– 1009.

    PubMed  CAS  Google Scholar 

  178. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104: 2187–93.

    PubMed  CAS  Google Scholar 

  179. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106: 2903–11.

    PubMed  CAS  Google Scholar 

  180. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Jr., Anderson WF et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341: 85–6.

    PubMed  CAS  Google Scholar 

  181. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994;84: 380–383.

    PubMed  CAS  Google Scholar 

  182. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94: 3325–33.

    PubMed  CAS  Google Scholar 

  183. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325: 1525–33.

    PubMed  CAS  Google Scholar 

  184. Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P et al. Outcome of high-dose therapy and autologous transplantation in non- Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol. 1996;14: 214–9.

    PubMed  CAS  Google Scholar 

  185. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342: 525–33.

    PubMed  CAS  Google Scholar 

  186. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993;82: 2605–10.

    PubMed  CAS  Google Scholar 

  187. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19: 337–42.

    PubMed  CAS  Google Scholar 

  188. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood. 1995;86: 390–7.

    PubMed  CAS  Google Scholar 

  189. Stong RC, Uckun F, Youle RJ, Kersey JH, Vallera DA. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood. 1985;66: 627–35.

    PubMed  CAS  Google Scholar 

  190. Webb IJ, Friedberg W, Gribben JG, Fisher DC, Spitzer T, Neuberg D et al. Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody -coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2002;8: 429–34.

    PubMed  CAS  Google Scholar 

  191. Cassileth PA, Anderson J, Lazarus HM, Calvin OM, Bennett JM, Stadtmauer EA et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. Journal of Clinical Oncology. 1993;11: 314–319.

    PubMed  CAS  Google Scholar 

  192. Laporte JP, Douay L, Lopez M, Labopin M, Jouet JP, Lessage S et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood. 1994;84: 3810–3818.

    PubMed  CAS  Google Scholar 

  193. Miyamoto T, Gondo H, Miyoshi Y, Shigematsu H, Minematsu T, Takenaka K et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol. 1998;100: 348–50.

    PubMed  CAS  Google Scholar 

  194. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999;94: 4029–35.

    PubMed  CAS  Google Scholar 

  195. Crippa F, Holmberg L, Carter RA, Hooper H, Marr KA, Bensinger W et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2002;8: 281–9.

    PubMed  Google Scholar 

  196. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005;23: 2240–7.

    PubMed  CAS  Google Scholar 

  197. van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol. 2006;132: 42–55.

    PubMed  Google Scholar 

  198. Hurd DD, LeBien TW, Lasky LC, Haake RJ, Ramsay NK, Kim TH et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med. 1988;85: 829–34.

    PubMed  CAS  Google Scholar 

  199. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16: 13–8.

    PubMed  CAS  Google Scholar 

  200. Anderson K, Andersen J, Soiffer R, Freedman A, Rabinowe S, Robertson M et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993;82: 2568–2576.

    PubMed  CAS  Google Scholar 

  201. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93: 1858–68.

    PubMed  CAS  Google Scholar 

  202. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19: 3771–9.

    PubMed  CAS  Google Scholar 

  203. Simonsson B, Burnett AK, Prentice HG, Hann IH, Brenner MK, Gibson B et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia. 1989;3: 631–6.

    PubMed  CAS  Google Scholar 

  204. Billett AL, Kornmehl E, Tarbell NJ, Weinstein HJ, Gelber RD, Ritz J et al. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993;81: 1651–1657.

    PubMed  CAS  Google Scholar 

  205. Soiffer RJ, Roy DC, Gonin R, Murray C, Anderson KC, Freedman AS et al. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993;12: 243–51.

    PubMed  CAS  Google Scholar 

  206. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992;79: 2229-ȓ36.

    PubMed  CAS  Google Scholar 

  207. Ball ED, Wilson J, Phelps V, Neudorf S. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up. Bone Marrow Transplant. 2000;25: 823–9.

    PubMed  CAS  Google Scholar 

  208. Miller CB, Rowlings PA, Zhang MJ, Jones RJ, Piantadosi S, Keating A et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol. 2001;29: 1336–46.

    PubMed  CAS  Google Scholar 

  209. Abdallah A, Egerer G, Weber-Nordt RM, Korbling M, Haas R, Ho AD. Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia. Bone Marrow Transplant. 2002;30: 15–22.

    PubMed  CAS  Google Scholar 

  210. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol. 1996;14: 2454–64.

    PubMed  CAS  Google Scholar 

  211. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90: 4212–21.

    PubMed  CAS  Google Scholar 

  212. Weisdorf DJ, Haake R, Miller WJ, McGlave PB, LeBien TW, Vallera DA et al. Autologous bone marrow transplantation for progressive non-Hodgkin's lym-phoma: clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant. 1991;8: 135–42.

    PubMed  CAS  Google Scholar 

  213. De Rosa L, Lalle M, Pandolfi A, Ruscio C, Amodeo R. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission. Ann Hematol. 2002;81: 575–81.

    Google Scholar 

  214. Bierman PJ, Sweetenham JW, Loberiza FR, Jr., Taghipour G, Lazarus HM, Rizzo JD et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21: 3744–53.

    PubMed  Google Scholar 

  215. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21: 3918–27.

    PubMed  CAS  Google Scholar 

  216. Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H et al. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32: 681–6.

    PubMed  CAS  Google Scholar 

  217. Imai Y, Chou T, Tobinai K, Tanosaki R, Morishima Y, Ogura M et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells:purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant. 2005;35: 479–87.

    PubMed  CAS  Google Scholar 

  218. Gisselbrecht C. In vivo purging and relapse prevention following ASCT. Bone Marrow Transplant. 2002;29 Suppl 1: S5–9.

    Google Scholar 

  219. Vogel W, Kopp HG, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131: 214–8.

    PubMed  Google Scholar 

  220. Lemoli RM, Martinelli G, Olivieri A, Motta MR, Rizzi S, Terragna C et al. Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. Br J Haematol. 1999;107: 419–28.

    PubMed  CAS  Google Scholar 

  221. Rasmussen T, Bjorkstrand B, Andersen H, Gaarsdal E, Johnsen HE. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol. 2002;30: 82–8.

    PubMed  Google Scholar 

  222. Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol. 2002;116: 202–10.

    PubMed  Google Scholar 

  223. Gupta D, Bybee A, Cooke F, Giles C, Davis JG, McDonald C et al. CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol. 1999;104: 166–77.

    PubMed  CAS  Google Scholar 

  224. Patriarca F, Damiani D, Fanin R, Grimaz S, Geromin A, Cerno M et al. Highdose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Haematologica. 2000;85: 269–74.

    PubMed  CAS  Google Scholar 

  225. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophospha-mide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998;22: 865–72.

    PubMed  CAS  Google Scholar 

  226. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339: 1649–56.

    PubMed  CAS  Google Scholar 

  227. Papadopoulos EB, Carabasi MH, Castro—Maraspina H, et al. T-cell-depleted all-ogenous bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91: 1083–90

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

    Vincent T. Ho

Authors
  1. Vincent T. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ho, V.T. (2008). Graft Manipulation: T Cell Depletion and Tumor Cell Purging. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_27

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation